Management of Oligometastatic Disease in Advanced Non–Small Cell Lung Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lussier, 2012, Oligo- and polymetastatic progression in lung metastasis(es) is associated with specific microRNAs, PLoS One, 7, e50141, 10.1371/journal.pone.0050141
Giaj-Levra, 2019, Defining synchronous oligometastatic non-small cell lung cancer: a systematic review, J Thorac Oncol, 14, 2053, 10.1016/j.jtho.2019.05.037
Dingemans, 2019, Definition of synchronous oligometastatic (sOMD)-NSCLC: a consensus report, J Thorac Oncol, 14, 2109, 10.1016/j.jtho.2019.07.025
Magilligan, 1986, Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years’ experience, Ann Thorac Surg, 42, 360, 10.1016/S0003-4975(10)60536-X
Flannery, 2008, Long-term survival in patients with synchronous, solitary brain metastases from non-small-cell lung cancer treated with radiosurgery, Int J Radiat Oncol Biol Phys, 72, 19, 10.1016/j.ijrobp.2007.12.031
Tanvetyanon, 2008, Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis, J Clin Oncol, 26, 1142, 10.1200/JCO.2007.14.2091
Ashworth, 2014, An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer, Clin Lung Cancer, 15, 346, 10.1016/j.cllc.2014.04.003
Guerra, 2012, Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis, Int J Radiat Oncol Biol Phys, 84, e61, 10.1016/j.ijrobp.2012.02.054
Yu, 2013, Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancer that have developed acquired resistance to EGFR tyrosine kinase inhibitors, J Thorac Oncol, 8, 346, 10.1097/JTO.0b013e31827e1f83
Weickhardt, 2012, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 7, 1807, 10.1097/JTO.0b013e3182745948
Ettinger
Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy; a multicentre, randomised, controlled, phase 2 study, Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0
Gomez, 2019, Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study, J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201
Iyengar, 2017, Consolidative radiotherapy for limited metastatic non-small-cell lung cancer, JAMA Oncol, 4, e173501, 10.1001/jamaoncol.2017.3501
Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5
Rusthoven, 2009, Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis, Acta Oncol, 48, 578, 10.1080/02841860802662722
Peng P, Chen Y, Han G, et al. Concomitant SBRT and EGFR-TKU versus EGFR-TKI alone for oligometastatic NSCLC: a multicenter, randomized phase II study. IASLC World Conf on Lung Cancer. Barcelona, Spain, A#MA01.09, September, 2019.
Ngwa, 2018, Using immunotherapy to boost the abscopal effect, Nat Rev Cancer, 18, 313, 10.1038/nrc.2018.6
Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774
Reck, 2019, Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small cell lung cancer with PD-L1 tumor proportion score of 50% or greater, J Clin Oncol, 37, 537, 10.1200/JCO.18.00149
Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer, N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005
Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer, N Engl J Med, 379, 2040, 10.1056/NEJMoa1810865
Demaria, 2012, Radiation as an immunological adjuvant: current evidence on dose and fractionation, Front Oncol, 2, 153, 10.3389/fonc.2012.00153
Dovedi, 2017, Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade, Clin Cancer Res, 23, 5514, 10.1158/1078-0432.CCR-16-1673
Gong, 2017, Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer, J Thorac Oncol, 12, 1085, 10.1016/j.jtho.2017.04.014
Theelen, 2019, Effect of pembrolizumab after stereotactic body radiotherapy vs. pembrolizumab alone on tumor response in patients with advanced non-cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial, JAMA Oncol, 5, 1276, 10.1001/jamaoncol.2019.1478
Bauml, 2019, Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer, JAMA Oncol, 5, 1283, 10.1001/jamaoncol.2019.1449
Griffioen, 2013, Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors, Lung Cancer, 82, 95, 10.1016/j.lungcan.2013.07.023
Milano, 2010, Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ, Am J Clin Oncol, 33, 157, 10.1097/COC.0b013e3181979238
Salama, 2008, An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease, Clin Cancer Res, 14, 5255, 10.1158/1078-0432.CCR-08-0358
Conibear, 2018, Study protocol for the SARON trial: a multicenter, randomised, controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer, BMJ Open, 8, e020690, 10.1136/bmjopen-2017-020690